No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH
A seven-year pregnancy registry study found no evidence of increased risk for major structural birth defects in infants exposed to the drug dupilumab in utero. The findings suggest the drug is safe for use during pregnancy when compared to disease-matched control groups.
Why it matters
This study provides critical safety data for clinicians treating pregnant patients with atopic dermatitis or asthma, addressing a previously unstudied population.
Dupilumab in Pregnant Women: An Unstudied Population?
Final results from a 7-year prospective pregnancy registry for dupilumab found no evidence of increased risk for major structural birth defects among infants exposed to the drug in utero, according to Christina D. Chambers, PhD, MPH, professor of pediatrics at UC San Diego and president of OTIS. Chambers discussed the registry data, presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, held September 30-October 3, in an interview with HCPLive.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in